Reviewing AIM ImmunoTech (NYSE:AIM) and Finch Therapeutics Group (NASDAQ:FNCH)

Finch Therapeutics Group (NASDAQ:FNCHGet Free Report) and AIM ImmunoTech (NYSE:AIMGet Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Profitability

This table compares Finch Therapeutics Group and AIM ImmunoTech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Finch Therapeutics Group N/A -136.63% -57.40%
AIM ImmunoTech -10,764.25% -67.33% -59.60%

Risk & Volatility

Finch Therapeutics Group has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of -0.13, meaning that its share price is 113% less volatile than the S&P 500.

Institutional and Insider Ownership

21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by company insiders. Comparatively, 0.0% of AIM ImmunoTech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Finch Therapeutics Group and AIM ImmunoTech, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Finch Therapeutics Group 0 0 0 0 N/A
AIM ImmunoTech 0 0 0 0 N/A

Finch Therapeutics Group currently has a consensus target price of $210.00, indicating a potential upside of 7,976.61%. Given Finch Therapeutics Group’s higher possible upside, equities analysts plainly believe Finch Therapeutics Group is more favorable than AIM ImmunoTech.

Earnings & Valuation

This table compares Finch Therapeutics Group and AIM ImmunoTech’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Finch Therapeutics Group $110,000.00 38.05 -$114.65 million ($47.67) -0.05
AIM ImmunoTech $140,000.00 164.31 -$19.44 million ($0.43) -1.10

AIM ImmunoTech has higher revenue and earnings than Finch Therapeutics Group. AIM ImmunoTech is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.

Summary

Finch Therapeutics Group beats AIM ImmunoTech on 7 of the 12 factors compared between the two stocks.

About Finch Therapeutics Group

(Get Free Report)

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

About AIM ImmunoTech

(Get Free Report)

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.